Earlier this month the Centers for Medicare and Medicaid Services released four new proposals to amend portions of the Sunshine Act.
There are four proposed changes:
a) Eliminate the continuing medical education (CME) exclusion from reporting requirements.
b) Require companies to specify the marketed name of a drug, device, biologic or medical supply associated with a certain payment whereas previously companies could simply identify the therapeutic area or product category.
c) Require companies to report to report stock, stock options or any other ownership interest as distinct categories.
d) Eliminate the definition of "covered device."
As many experts responded, the ink is barely dry...